Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OmpK36 vaccine
- Development stage
- Preclinical
- Lead developer
- National Health Research Institutes
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intranasal, Subcutaneous
01
Overview
The OmpK36 vaccine is a recombinant protein subunit vaccine targeting the outer membrane protein K36 (OmpK36) of *Klebsiella pneumoniae*. Developed by the National Health Research Institutes (NHRI) of Taiwan, the vaccine is designed to prevent *K. pneumoniae* infections, particularly urinary tract infections (UTIs). It is formulated with PELC, a squalene-based oil-in-water emulsion adjuvant containing poly(ethylene glycol)-block-poly(lactide-co-ε-caprolactone) (PEG-b-PLACL) and Span 85, which enhances mucosal and systemic immune responses. Administered intranasally or subcutaneously, the vaccine induces OmpK36-specific IgG and IgA antibodies, providing protective immunity against *K. pneumoniae* infections.
- Other names
- PELC-OmpK36PELC-OmpK-36PELC-OmpK 36outer membrane protein K36 vaccinerOmpK36 vaccinerOmpK-36 vaccinerOmpK 36 vaccinerecombinant OmpK36 vaccine
02
Targets
Neuraminidase
Beyond the preview
Go deeper on OmpK36 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OmpK36 vaccine.